Difference between revisions of "FLT3"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
 
(16 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
==Primary Author(s)*==
 
==Primary Author(s)*==
  
−
Dr Kay Weng Choy MBBS, BMedSci, FAACB, Monash Health
+
Kay Weng Choy, MBBS, Monash Medical Centre
  
 
__TOC__
 
__TOC__
Line 21: Line 21:
 
==Cancer Category/Type==
 
==Cancer Category/Type==
  
−
Acute myeloid leukemia (AML)
+
[[HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]
  
−
==Gene Overview==
+
[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
−
 
 
−
''FLT3'' is a member of the type III receptor tyrosine kinase family that regulates hematopoiesis [1]. The receptor is activated by binding of the FLT3 ligand to the extracellular domain, which leads to homodimer formation in the plasma membrane and consequently autophosphorylation of tyrosine residues in the receptor; the activated receptor kinase then phosphorylates and activates multiple cytoplasmic effector molecules involved in proliferation and differentiation of hematopoietic cells in the bone marrow [2]. ''FLT3'' contains five functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), an interrupted tyrosine kinase domain (TKD), and a small C-terminal domain [3].
 
  
 
''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.
 
''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.
  
−
Differences in expression levels [measured using the FLT3-ITD-to-wild-type (WT) allelic ratio] have prognostic implications [3,7,8,9]. It is commonly agreed that a high FLT3-ITD-to-wild-type allelic ratio is a negative prognostic factor (regardless of cytogenetics); the 2017 European Leukemia Net (ELN) guidelines defined 0.5 as the cut-off between low and high allelic ratios [10]. ''FLT3''-ITD remains relevant as a prognostic factor even after intensive chemotherapy and/or stem cell transplant [3]. ''FLT3'' testing was historically viewed as being purely prognostic; however, with the advent of ''FLT3'' inhibitors, it will likely be considered as both prognostic (clinical outcome) and predictive (treatment benefit) [3].
+
==Gene Overview==
−
The second most common type of ''FLT3'' mutations in AML are those within the TKD (occurring in up to 14% of adult patients with AML) [3]. The majority are point mutations within the activation loop (e.g., residues D835, I836, Y842) of the TKD2, and within the TKD1 (e.g., residues N676, F691) [3,11]. As a result of amino acid substitutions, changes in the activation loop favor the active kinase confirmation. The prognostic significance of ''FLT3''-TKD mutations is controversial and may depend on additional mutations and cytogenetics [3].
 
  
−
''FLT3''-ITD and ''FLT3''-TKD mutations are common in patients with AML with normal karyotype but they can also be associated with abnormal karyotype, such as t(15;17)/PML-RARA and core binding factor (''CBF'') AML. ''FLT3''-ITD is frequently associated with t(6;9)(p23;q34.1) abnormalities [12]. The prognosis for patients with ''FLT3'' mutations can be affected by the presence or absence of additional mutations. Patients who are ''FLT3''-ITD negative (''FLT3''-ITD-) or ''FLT3''-ITD low and positive for nucleophosmin 1 mutations (NPM1+) have a “favorable” prognosis; patients who are FLT3-ITD- (or FLT3-ITDlow) with NPM1-WT have an intermediate prognosis [10]. On the other hand, patients who are FLT3-ITDhigh with NPM1-WT have a “poor” prognosis and are less likely to achieve complete remission (CR) with induction chemotherapy than patients with other ''FLT3''/''NPM1'' combinations [3,13].  
+
''FLT3'' is a member of the type III receptor tyrosine kinase family that regulates hematopoiesis [1]. The receptor is activated by binding of the FLT3 ligand to the extracellular domain, which leads to homodimer formation in the plasma membrane and consequently autophosphorylation of tyrosine residues in the receptor; the activated receptor kinase then phosphorylates and activates multiple cytoplasmic effector molecules involved in proliferation and differentiation of hematopoietic cells in the bone marrow [2]. ''FLT3'' contains five functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), an interrupted tyrosine kinase domain (TKD), and a small C-terminal domain [3].
−
 
 
−
Allogeneic hematopoietic stem cell transplant (alloHSCT) is generally recommended for patients with ''FLT3''-ITD mutations in first complete remission (CR1), provided they are eligible for transplant therapy and have a suitable donor. Among patients with ''FL3''-ITD mutations in ''CR1'', those who undergo alloHSCT have significantly better outcomes (e.g., prolonged survival and decreased risk of relapse) than those who receive chemotherapy alone. Despite this, ''FLT3''-ITD remains a poor prognostic factor (high relapse rate and short relapse-free and overall survival) after alloHSCT and chemotherapy. Patients with ''FLT3''-ITD AML may benefit from the use of ''FLT3'' tyrosine kinase inhibitors as maintenance therapy to prevent relapse following alloHSCT.
 
−
Given its prognostic and predictive values, it is argued that ''FLT3'' testing should be performed in all AMLs regardless of cytogenetics [3]. If the ''FLT3''-ITD-to-WT allelic ratio is used for risk stratification, harmonisation of ''FLT3'' testing is essential to ensure that comparable results are achieved [3].
 
  
 
==Common Alteration Types==
 
==Common Alteration Types==
  
−
In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD. See Figure in [3].
+
In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD. See Figure in [3]. The second most common type of ''FLT3'' mutations in AML are those within the TKD (occurring in up to 14% of adult patients with AML) [3]. The majority are point mutations within the activation loop (e.g., residues D835, I836, Y842) of the TKD2, and within the TKD1 (e.g., residues N676, F691) [3,7]; activating mutations caused by insertions (e.g., insertion of glycine and serine between residues S840 and N841) and deletions have also been found in TKD [3]. Additional ''FLT3'' point mutations that have been found in patients with AML include mutations within the extracellular domain (e.g. T167, V194, D324, Y364, and V491), transmembrane domain (e.g., I548, V557), JMD (e.g., V579, E598), TKD1 (e.g., A680, M737), and TKD2 (e.g., V816, A814, T784). See Figure in [3].
−
 
 
−
The second most common type of ''FLT3'' mutations in AML are those within the TKD (occurring in up to 14% of adult patients with AML) [3]. The majority are point mutations within the activation loop (e.g., residues D835, I836, Y842) of the TKD2, and within the TKD1 (e.g., residues N676, F691) [3,11]; activating mutations caused by insertions (e.g., insertion of glycine and serine between residues S840 and N841) and deletions have also been found in TKD [3].
 
−
 
 
−
Additional ''FLT3'' point mutations that have been found in patients with AML include mutations within the extracellular domain (e.g. T167, V194, D324, Y364, and V491), transmembrane domain (e.g., I548, V557), JMD (e.g., V579, E598), TKD1 (e.g., A680, M737), and TKD2 (e.g., V816, A814, T784). See Figure in [3].
 
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
−
! Copy Number Loss   !! Copy Number Gain   !! LOH   !!   Loss-of-Function Mutation   !! Gain-of-Function Mutation !! Translocation/Fusion  
+
!Copy Number Loss!!Copy Number Gain!!LOH!!Loss-of-Function Mutation!!Gain-of-Function Mutation!!Translocation/Fusion
 
|-
 
|-
−
| || ||   || || X ||  
+
| || || || ||X||
 
|}
 
|}
  
 
==Internal Pages==
 
==Internal Pages==
  
−
Not applicable.
+
[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
  
 
==External Links==
 
==External Links==
Line 92: Line 82:
 
6. Patel JP, et al., (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079-1089. PMID 22417203.
 
6. Patel JP, et al., (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079-1089. PMID 22417203.
  
−
7. Thiede C, et al., (2002). Analysis of FLT3- activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326-4335. PMID 12036858.
+
7. Smith CC, et al., (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263. PMID 22504184.
  
−
8. Pratcorona M, et al, (2002). Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121:2734-2738. PMID 23377436.
+
==Notes==
−
 
+
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
−
9. Gale RE, et al., (2008). The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776-2784. PMID 17957027.
 
−
 
 
−
10. Dohner H, et al., (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424-447. PMID 27895058.
 
  
−
11. Smith CC, et al., (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263. PMID 22504184.
+
[[Category:Cancer Genes F]]
−
 
 
−
12. Oyarzo MP, et al., (2004). Acute myeloid leukemia with t(6;9) (p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 122(3):348-358. PMID 15362364.
 
−
 
 
−
13. Walter RB, et al., (2015). Resistance prediction in AML: analysis of 4601 patients from MRC/ NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29(2):312-320. PMID 255113226.
 
−
 
 
−
== Notes ==
 
−
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
 

Latest revision as of 14:20, 12 December 2023

Primary Author(s)*

Kay Weng Choy, MBBS, Monash Medical Centre

Synonyms

Fms Related Tyrosine Kinase 3, Fms-like Tyrosine Kinase 3

Genomic Location

Cytoband: 13q12.2

Genomic Coordinates:

chr13:28,577,411-28,674,729 (GRCh37/hg19)

chr13:28,003,274-28,100,592 (GRCh38/hg38)

Cancer Category/Type

HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement

FLT3 mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in FLT3 and they occur in up to 30% of adult patients with de novo AML [3,4,5,6]. About 70% of FLT3-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.

Gene Overview

FLT3 is a member of the type III receptor tyrosine kinase family that regulates hematopoiesis [1]. The receptor is activated by binding of the FLT3 ligand to the extracellular domain, which leads to homodimer formation in the plasma membrane and consequently autophosphorylation of tyrosine residues in the receptor; the activated receptor kinase then phosphorylates and activates multiple cytoplasmic effector molecules involved in proliferation and differentiation of hematopoietic cells in the bone marrow [2]. FLT3 contains five functional domains: an immunoglobulin-like extracellular domain, a transmembrane domain, a juxtamembrane domain (JMD), an interrupted tyrosine kinase domain (TKD), and a small C-terminal domain [3].

Common Alteration Types

In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in FLT3 and they occur in up to 30% of adult patients with de novo AML [3,4,5,6]. About 70% of FLT3-ITDs occur in the JMD and about 30% in the TKD. See Figure in [3]. The second most common type of FLT3 mutations in AML are those within the TKD (occurring in up to 14% of adult patients with AML) [3]. The majority are point mutations within the activation loop (e.g., residues D835, I836, Y842) of the TKD2, and within the TKD1 (e.g., residues N676, F691) [3,7]; activating mutations caused by insertions (e.g., insertion of glycine and serine between residues S840 and N841) and deletions have also been found in TKD [3]. Additional FLT3 point mutations that have been found in patients with AML include mutations within the extracellular domain (e.g. T167, V194, D324, Y364, and V491), transmembrane domain (e.g., I548, V557), JMD (e.g., V579, E598), TKD1 (e.g., A680, M737), and TKD2 (e.g., V816, A814, T784). See Figure in [3].

Copy Number Loss Copy Number Gain LOH Loss-of-Function Mutation Gain-of-Function Mutation Translocation/Fusion
X

Internal Pages

HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement

External Links

FLT3 by Atlas of Genetics and Cytogenetics in Oncology and Haematology - detailed gene information

FLT3 by COSMIC - sequence information, expression, catalogue of mutations

FLT3 by CIViC - general knowledge and evidence-based variant specific information

FLT3 by Precision Medicine Knowledgebase (Weill Cornell) - manually vetted interpretations of variants and CNVs

FLT3 by Cancer Genetics Web - gene, pathway, publication information matched to cancer type

FLT3 by OncoKB - mutational landscape, mutation effect, variant classification

FLT3 by My Cancer Genome - brief gene overview

FLT3 by UniProt - protein and molecular structure and function

FLT3 by Pfam - gene and protein structure and function information

FLT3 by GeneCards - general gene information and summaries

References

1. Rosnet O, et al., (1996). Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10(2):238-248. PMID 8637232.

2. Liu, S, et al., (2014). MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123(5):734-742. PMID 24282218.

3. Patnaik MM, (2017). The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma 22:1-14. PMID 29164965.

4. Kayser S, et al., (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114(12):2386-2392. PMID 19602710.

5. Papaemmanuil E, et al, (2016). Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209-2221. PMID 27276561.

6. Patel JP, et al., (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079-1089. PMID 22417203.

7. Smith CC, et al., (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263. PMID 22504184.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Retrieved from "https://ccga.io/index.php?title=FLT3&oldid=13612"